Skip to main content
Caplight Logo









HexemBio

HexemBio

Private
New York City, New YorkHealthcare & Life Scienceshttps://hexemb.io/

Last Round

Seed

Apr 7, 2026

Total Funding Raised

$10.4M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

HexemBio is a biotechnology company that develops regenerative therapies for aging blood stem cells using its proprietary Synthetic Human Yolk Sac technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

regenerative therapyhematopoietic stem cellsHSCcell therapybone marrow transplantex vivo therapysynthetic nichebiotechlongevity sciencedrug discoveryprecision medicineclinical trialsbio-aiorphan drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HexemBio Comparables

Compare HexemBio with similar companies based on industry and business-model similarity.

HexemBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImmuneAGE Bio
83%
ExCellThera
76%
Mogling Bio Inc.
71%

HexemBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 7, 2026

HexemBio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors increased 79% MoM.

  • May 27, 2026

    Grew 175% QoQ from 4 to 11 employees.

HexemBio Filings

Explore SEC and related filing metadata, where available.

HexemBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about HexemBio's valuation, stock price, and market status.

Is HexemBio a public or private company?

HexemBio is a private company.

What is the current stock price of HexemBio?

HexemBio is a private company with no public stock price. No recent secondary market data is available.

How much is HexemBio worth (valuation)?

Valuation information for HexemBio is not publicly available.

Can I buy HexemBio stock?

HexemBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was HexemBio's last funding round?

HexemBio's most recent funding round was Seed on April 7, 2026.

Who are the main investors in HexemBio?

Key investors in HexemBio include Draper Associates.

Will HexemBio IPO soon?

No public IPO plans have been announced for HexemBio.

How can I track HexemBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor HexemBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range11
Year Founded2024
Last FundingApr 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?